Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2023 5
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
CALR mutation burden in essential thrombocythemia and disease outcome.
Guglielmelli P, Szuber N, Gangat N, Capecchi G, Maccari C, Harnois M, Karrar O, Abdelmagid M, Balliu M, Nacca E, Atanasio A, Sestini I, Désilets A, Loscocco GG, Rotunno G, Busque L, Tefferi A, Vannucchi AM. Guglielmelli P, et al. Among authors: karrar o. Blood. 2024 Mar 28;143(13):1310-1314. doi: 10.1182/blood.2023023428. Blood. 2024. PMID: 38252902
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.
Gangat N, Karrar O, Iftikhar M, McCullough K, Johnson IM, Abdelmagid M, Abdallah M, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar A, Saliba AN, Hefazi Torghabeh M, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Palmer J, Sproat L, Khera N, Arana Yi C, Tefferi A. Gangat N, et al. Among authors: karrar o. Am J Hematol. 2024 Feb;99(2):193-202. doi: 10.1002/ajh.27138. Epub 2023 Dec 10. Am J Hematol. 2024. PMID: 38071734
One thousand patients with essential thrombocythemia: the Mayo Clinic experience.
Gangat N, Karrar O, Al-Kali A, Begna KH, Elliott MA, Wolanskyj-Spinner AP, Pardanani A, Hanson CA, Ketterling RP, Tefferi A. Gangat N, et al. Among authors: karrar o. Blood Cancer J. 2024 Jan 18;14(1):11. doi: 10.1038/s41408-023-00972-x. Blood Cancer J. 2024. PMID: 38238303 Free PMC article.
Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events.
Abdelmagid MG, Al-Kali A, Litzow MR, Begna KH, Hogan WJ, Patnaik MS, Hashmi SK, Elliott MA, Alkhateeb H, Karrar OS, Fleti F, Elnayir MH, Rivera CE, Murthy HS, Foran JM, Kharfan-Dabaja MA, Badar T, Viswanatha DS, Reichard KK, Gangat N, Tefferi A. Abdelmagid MG, et al. Among authors: karrar os. Blood Cancer J. 2023 Aug 11;13(1):122. doi: 10.1038/s41408-023-00891-x. Blood Cancer J. 2023. PMID: 37567878 Free PMC article.
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival.
Karrar O, Abdelmagid M, Rana M, Iftikhar M, McCullough K, Al-Kali A, Alkhateeb HB, Begna KH, Elliott MA, Mangaonkar A, Saliba A, Hefazi Torghabeh M, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Palmer J, Sproat L, Khera N, Arana Yi C, Tefferi A, Gangat N. Karrar O, et al. Am J Hematol. 2024 Feb;99(2):E63-E66. doi: 10.1002/ajh.27180. Epub 2023 Dec 15. Am J Hematol. 2024. PMID: 38100217
Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia.
Gangat N, McCullough K, Abdelmagid M, Karrar O, Powell M, Al-Kali A, Alkhateeb H, Begna K, Mangaonkar A, Saliba A, Torghabeh MH, Litzow M, Hogan W, Shah M, Patnaik M, Pardanani A, Badar T, Foran J, Palmer J, Sproat L, Yi CA, Tefferi A. Gangat N, et al. Among authors: karrar o. Haematologica. 2024 Jan 1;109(1):187-292. doi: 10.3324/haematol.2023.283732. Haematologica. 2024. PMID: 37534525 Free PMC article. No abstract available.
Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents.
Johnson IM, Karrar O, Rana M, Iftikhar M, Chen S, McCullough K, Saliba AN, Al-Kali A, Alkhateeb H, Begna K, Litzow M, Hogan WJ, Shah M, Patnaik MM, Pardanani A, Hermann J, Tefferi A, Gangat N. Johnson IM, et al. Among authors: karrar o. Br J Haematol. 2024 Apr;204(4):1232-1237. doi: 10.1111/bjh.19325. Epub 2024 Feb 4. Br J Haematol. 2024. PMID: 38311378